<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> syndrome, characterized by beta-cell failure in the setting of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>T2DM has a progressive course and is associated with a high <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) risk, regardless of the treatment used </plain></SENT>
<SENT sid="2" pm="."><plain>The incretin hormones glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> (GLP)-1 and <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (GIP) are secreted in the gut upon meal ingestion and lower blood <z:chebi fb="105" ids="17234">glucose</z:chebi> by <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent stimulation of insulin secretion and production </plain></SENT>
<SENT sid="3" pm="."><plain>Exogenously administered GLP-1 lowers postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions by inhibiting glucagon secretion and delaying gastric emptying, improves beta-cell function, and promotes satiety and <z:hpo ids='HP_0001824'>weight loss</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Native GLP-1 is degraded rapidly by the ubiquitous enzyme dipeptidyl-peptidase (DPP)-4 </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, injectable DPP-4-resistant GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> (GLP-1RA) and oral DPP-4 inhibitors have been developed </plain></SENT>
<SENT sid="6" pm="."><plain>Exenatide is the first GLP-1RA that became available for the treatment of T2DM patients </plain></SENT>
<SENT sid="7" pm="."><plain>Exenatide has unique characteristics, as to date it is the only agent that addresses the multiple defects of the T2DM phenotype, including <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, islet-cell dysfunction, alimentary <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In animals, exenatide also increased beta-cell mass </plain></SENT>
<SENT sid="9" pm="."><plain>Long-term prospective studies in high-risk populations should address the potentially disease modifying effect of exenatide and its effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk, in addition to its safety and tolerability </plain></SENT>
</text></document>